THERALY FIBROSIS
Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of fibrotic disease including chronic pancreatitis, systemic sclerosis, and NASH. The company’s lead candidate, TLY012, selectively targets myofibroblasts, cells believed to be the critical originators of fibrosis, a condition that affects a variety of tissues.
THERALY FIBROSIS
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Germantown, Maryland, United States
Country:
United States
Website Url:
http://www.ddpharmatech.com
Total Employee:
11+
Status:
Active
Total Funding:
9.54 M USD
Similar Organizations
akta Pharmaceutical Development LLC
aktaPD is an international company that designs, develops, and commercializes treatments for various diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
CPSI Biotech
CPSI Biotech is an integrative bio-Medtech & healthcare firm whose mission is to develop life science research products & medical devices.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Theraly Fibrosis
Official Site Inspections
http://www.ddpharmatech.com
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Theraly Fibrosis"
디앤디파마텍
D&D Pharmatech is a company focused on developing treatments for metabolic dysfunction-associated steatohepatitis.See details»
D&D Pharmatech - Crunchbase Investor Profile & Investments
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by …See details»
D&D Pharmatech Company Profile | Management and Employees …
Www.ddpharmatech.com D&D Pharmatech Profile and History D&D Pharmatech is a clinical-stage global biotech company that funds the development of medicines through disease …See details»
D&D Pharmatech Co., Ltd. - Drug pipelines, Patents, Clinical
Jun 3, 2023 www.ddpharmatech.com. Startups | Public Company | 2014 | Gyeonggi-do, South Korea | 10-50 | www.ddpharmatech.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. …See details»
D&D Pharmatech | LinkedIn
D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs.See details»
D&D Pharmatech - PitchBook
Jul 18, 2018 D&D Pharmatech General Information Description. D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and …See details»
D&D Pharmatech - Craft
D&D Pharmatech has 5 employees across 2 locations and $155.61 m in total funding,. See insights on D&D Pharmatech including office locations, competitors, revenue, financials, …See details»
D&D Pharmatech - VentureRadar
"D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided …See details»
D&D Pharmatech Granted Fast Track Designation from US FDA for …
Apr 2, 2024 About DD01. DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors with a half-life of 7-8 days in obese/overweight patients …See details»
D&D Pharmatech Raises $51M in Series C Financing to …
Oct 19, 2021 GYEONGGI-DO, Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and ...See details»
D&D Pharmatech Raises $51M in Series C Financing to Advance
Oct 19, 2021 GYEONGGI-DO, Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)-- D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and …See details»
D&D Pharmatech Appoints Yoo-Seok Hong as Chief Executive …
Jun 15, 2021 D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, toSee details»
D&D Pharmatech Announces Sponsored Research Agreement …
Apr 20, 2021 D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, toSee details»
D&D Pharmatech Announces Rapid, Clinically Significant
May 2, 2023 D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced positive topline results from its …See details»
D&D Pharmatech | VentureRadar
Website: http://www.ddpharmatech.com. Develops and funds revolutionary medicines through disease-specific subsidiaries, focusing on neurodegenerative, fibrotic ...See details»
D&D Pharmatech Announces Rapid, Clinically Significant …
May 2, 2023 D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced posiSee details»
D&D Pharmatech Raises $137.1M in Series B Financing to Advance ...
Aug 14, 2019 Proceeds to Support Development of Clinical Parkinson’s and Alzheimer’s Candidates and Preclinical Fibrosis Candidate. Financing Led by Octave Life Sciences, joined …See details»
D&D Pharmatech Co., Ltd. (D&D Pharmatech Co., Ltd.) - 药物管线_ …
了解D&D Pharmatech Co., Ltd. (D&D Pharmatech Co., Ltd.)公司的药物管线，治疗领域，技术平台，以及它的6项临床试验, 38篇新闻和11篇文献，疾病领域:内分泌与代谢疾病，肿瘤，神经 …See details»
D&D Pharmatech Announces Agreement with Salubris …
Sep 27, 2021 D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and …See details»
D&D Pharmatech Announces First Patient Dosed in Phase 1 …
Mar 30, 2021 DD01 is a long-acting dual agonist of GLP-1 and glucagon receptors, which resulted in weight loss, improved metabolic control and reduced fatty liver in animal models of …See details»